Executive Order 14221 represents a significant assertion of executive power in the realm of healthcare policy. While framed as an effort to benefit patients through price transparency, the order raises serious concerns regarding constitutional limits on executive authority, democratic processes, and the rule of law. The unilateral nature of the order, the broad delegation of authority to multiple agencies, and the potential for arbitrary enforcement are all red flags. The stalling of progress from a previous administration further suggests a pattern of executive-led policy implementation that may bypass legislative consensus and institutional continuity.